Spots Global Cancer Trial Database for rilotumumab
Every month we try and update this database with for rilotumumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| AMG 102 and Avastin for Recurrent Malignant Glioma | NCT01113398 | Glioblastoma Mu... Gliosarcoma | AMG 102 Avastin | 18 Years - | Duke University | |
| AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma | NCT01105390 | Advanced Malign... Epithelial Meso... Recurrent Malig... Sarcomatous Mes... | rilotumumab cisplatin pemetrexed diso... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma | NCT01697072 | Gastric Cancer | Rilotumumab Placebo Epirubicin Cisplatin Capecitabine | 18 Years - 99 Years | Amgen | |
| Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches | NCT02926638 | MET Positive Recurrent Squam... Stage IV Squamo... | Erlotinib Hydro... Laboratory Biom... Rilotumumab | 18 Years - | SWOG Cancer Research Network | |
| First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma | NCT01697072 | Gastric Cancer | Rilotumumab Placebo Epirubicin Cisplatin Capecitabine | 18 Years - 99 Years | Amgen | |
| Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches | NCT02926638 | MET Positive Recurrent Squam... Stage IV Squamo... | Erlotinib Hydro... Laboratory Biom... Rilotumumab | 18 Years - | SWOG Cancer Research Network | |
| Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC) | NCT00788957 | Colon Cancer Colorectal Canc... Gastrointestina... Metastatic Colo... Rectal Cancer | Panitumumab Ganitumab Rilotumumab Placebo | 18 Years - | Amgen | |
| First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma | NCT01697072 | Gastric Cancer | Rilotumumab Placebo Epirubicin Cisplatin Capecitabine | 18 Years - 99 Years | Amgen | |
| A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer | NCT02137343 | Gastric Cancer | Rilotumumab Placebo Cisplatin Capecitabine | 20 Years - 100 Years | Amgen | |
| A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer | NCT02137343 | Gastric Cancer | Rilotumumab Placebo Cisplatin Capecitabine | 20 Years - 100 Years | Amgen | |
| Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | NCT01039207 | Recurrent Fallo... Recurrent Ovari... Recurrent Prima... | Laboratory Biom... Rilotumumab | 18 Years - | GOG Foundation | |
| Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches | NCT02926638 | MET Positive Recurrent Squam... Stage IV Squamo... | Erlotinib Hydro... Laboratory Biom... Rilotumumab | 18 Years - | SWOG Cancer Research Network | |
| AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma | NCT01105390 | Advanced Malign... Epithelial Meso... Recurrent Malig... Sarcomatous Mes... | rilotumumab cisplatin pemetrexed diso... laboratory biom... | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
